Introduction
Crohn's disease (CD) is a heterogeneous, relapsing inflammatory condition that can affect any part of the gastrointestinal tract (GIT). The commonest locations affected are the terminal ileum and colon, whereas oral to mid-ileal involvement accounts for less than 5% of cases. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Gottlieb et al. described the first case of proximal CD in 1937 in a patient with duodenal disease. 12 The Montreal and Vienna classifications define proximal CD as involvement proximal to the terminal ileum 13, 14 ; however, the majority of the literature is limited to disease within and proximal to the duodenum, which will be the focus of this review.
Epidemiology
The majority of studies reporting on proximal CD are retrospective cohort studies rather than population-based studies, most frequently quoting a prevalence of 0.5-16%. 3, [15] [16] [17] [18] [19] [20] [21] Although small bowel investigations are rarely performed routinely in the absence of proximal intestinal symptoms, 18, 22 the increased availability of small bowel investigations such as wireless capsule endoscopy, computed tomography (CT), and magnetic resonance enterography has led to increased reporting of proximal CD cases. 22 There are several different classification systems for diagnosing upper GIT CD, including the Lennard-Jones criteria, 23 Vienna classification, 14 and the Nugent and Roy criteria, 24 which assess gastroscopy findings, histology, and/or symptomatology. Wireless capsule endoscopy, small bowel follow-through, and enterography may also be used to aid diagnosis. Criteria that do not require the presence of clinical symptoms, such as Nugent and Roy, allow the diagnosis to be made in asymptomatic patients, potentially resulting in a higher disease prevalence. 25 Male sex predominance is observed in proximal CD with a sex ratio of 1.2:1. [24] [25] [26] The age of diagnosis is lower in both adults and children. 19, 25, [27] [28] [29] In adults, the mean age of diagnosis in proximal CD versus distal CD is 21.2 versus 25.4 years. 19, 29 Pediatric patients with proximal CD are diagnosed at a mean of 10.9 years, compared with 12.6 years for distal disease. 27 Compared with distal CD, smoking prevalence at the time of diagnosis is also lower at 15% versus 22%. 19 There is no association between disease location and alcohol or medication use. 18, 26, 30 Isolated upper GIT CD without ileal or colonic disease is rare. 17, 25 A cross-sectional study of 2105 CD patients by Lazarev et al. 19 identified 346 (16%) cases of proximal disease (8.3% esophagogastroduodenal, 5.5% jejunal, and 2.6% both). Coexisting distal disease was found in 321 of these 346 patients (93%). Upper GIT symptoms presented before distal symptoms in only 8-10% of CD patients, suggesting that this phenotype is typically preceded by a long asymptomatic phase. 15, 25, 31 Wagtmans et al. 32 identified upper GIT involvement in 72 of 940 CD patients studied (7.6%). Seven of these 72 (9.7%) patients initially presented with isolated upper GIT involvement, one of whom remained free from distal GIT disease after an 8-year follow-up period. Isolated distal GIT CD was the initial diagnosis in 45 of 72 patients (62.5%), before they subsequently developed proximal GIT CD after an average interval of 5 years.
Diagnosis
The diagnosis of upper GIT CD is made by a combination of symptoms, gastroscopy, enteroscopy, capsule endoscopy, histopathology, and imaging. 22 The most sensitive investigation is gastroscopy with biopsies for histopathology. 33 Capsule endoscopy is more sensitive than barium imaging for detection of small intestinal CD, with Fireman and Kopelman reporting a yield of 63% versus 23%. 34, 35 However, capsule endoscopy has been found to lack specificity in comparison with other imaging modalities. 36 Most patients diagnosed with upper GIT disease are either asymptomatic (62.5%) 18, 32 or have nonspecific symptoms, therefore supporting the role of routine gastroscopy and/or radiology for all CD patients. 18, 27 The Asia-Pacific consensus statement recommends performing a diagnostic gastroscopy for assessment of pediatric CD and undifferentiated inflammatory bowel disease. 36 Gastroscopy identifies macroscopic lesions in 20-64% of patients and microscopic disease in 40-70%, although these features may not be specific to CD and their clinical relevance is unclear. 18, 37, 38 Nonspecific symptoms including weight loss, dyspepsia, heartburn, belching, bloating, or vomiting require exclusion of other diseases, such as peptic ulceration. 18, 39, 40 The diagnosis of upper GIT CD can be made without concomitant lower GIT involvement; however, presence of ileocolonic CD may expedite the diagnosis. Lower GIT CD is similarly diagnosed via endoscopy (ileocolonoscopy) with biopsies and/or imaging studies in a patient with a compatible clinical history. 36 Fecal calprotectin and lactoferrin offer diagnostic utility for colonic CD; however, they are not reliable indicators of upper GIT CD involvement. 41 Nugent and Roy have proposed diagnostic criteria for upper GIT CD 24 composing of either 1 distinctive histology with non-caseating granulomas, with or without CD elsewhere in the GIT, in absence of a systemic granulomatous condition, or 2 radiologic or endoscopic evidence of diffuse inflammation consistent with CD, in addition to diagnosed CD elsewhere in the GIT.
Oral disease
Oral involvement in patients with intestinal CD is typically termed oral Crohn's disease (OCD). 42 Although well described and classified, they are often unrecognized or overlooked by gastroenterologists. 4 The reported prevalence of OCD is highly variable, depending on the ethnicity and age of the population studied and involvement (or not) of an oral medicine or dentistry specialist. 7, 43, 44 Rowland et al. prospectively evaluated a cohort of children attending a dedicated specialist multidisciplinary oral and gastrointestinal diseases clinic. 42 The authors reported a prevalence of OCD in up to 41.7% of children, at a mean age of 12.4 months. In adults, the prevalence of OCD appears to be lower at approximately 20%, but has been reported as high as 50%. 7, 42, 44 Comparatively, OCD patients have a lower age of presentation than the average CD population. 45 There is also a greater degree of perianal involvement in patients with OCD than those with intestinal CD.
The recognition and diagnosis of OCD is made more difficult by another disease entity known as orofacial granulomatosis (OFG) that is clinically and histopathologically indistinguishable from OCD. The term OFG, proposed by Wiesenfield et al., encompasses conditions of the orofacial region associated with enlargement of the lips, mucosal and gingival infiltration, and oral ulceration demonstrating non-caseating granulomas on biopsy. The diagnosis is made in the absence of identifiable intestinal CD or sarcoidosis. 46 On histopathology, both OCD and OFG feature a chronic inflammatory cell infiltrate and non-caseating granulomas. 47 OFG appears to be genetically distinct from OCD despite their clinical and histopathological similarities. 48 The exclusion of infectious causes, in particular, tuberculosis, atypical mycobacterial infection, tertiary syphilis, and rare mycotic infections (Cryptococcus and Histoplasma) is also necessary. 42, 49 The clinical presentation of OCD is highly variable. The most frequently involved areas are the lips, followed by buccal mucosa and gingival (Fig. 1) . 50 Swelling of the lips in OCD can be unilateral or involve the entire lip. The lower lip is typically more frequently involved than the upper lip, which may be in part due to its greater effect on cosmesis leading to increased reporting (Fig. 1a) . The affected lip will feel indurated and is usually painless, even on firm palpation. "Cobblestoning" (fissuring and serpiginous ulceration) of the buccal mucosa bilaterally usually affects the mandibular buccal sulcus but spares the maxillary buccal sulcus (Fig. 1b,c) . These "aphthous-like" ulcers are usually linear, run along the length of the buccal sulcus or alveolar mucosa, and are often mistaken for aphthous ulcers. In contrast, the ulcers of true recurrent aphthous stomatitis are neatly ovoid or circular in shape (Fig. 2) . They have a yellow-gray center and a distinct red halo, with no associated systemic condition. 51 The ulceration and fissuring can be associated with individual mucosal tags, up to several millimeters in length and diameter. Gingival swelling and infiltration is also frequently seen in OCD (Fig. 1d ) and can extend beyond the gingiva to involve the adjacent alveolar mucosa. Involvement of other tissue sites, such as the palate, is uncommon.
There is limited data available on differentiating the clinical features distinct to OCD compared with OFG. Lip swelling is less common and less severe in OCD patients than those with OFG, while buccal sulcal involvement with ulceration and presence of mucosal tags is more frequent and extensive in patients with OCF than OFG. Regardless, the presence of any or one of these clinical features warrants biopsy. Notably, a proportion of patients who initially present with features of OFG go on to develop CD of the intestine, indicating the need for close clinical monitoring of such "OFG only" patients. 43 Treatment. Treatment for OCD needs to be consistent with the overall management of the patient's CD. With regard to treatment response, the clinical features of OCD can behave differently and independently of the intestinal CD. Treatment for OCD ranges from topical medicaments to systemic treatment, sometimes in addition to those required for the control of the intestinal CD. 52 Topical corticosteroid ointments and mouthwashes are the mainstay of initial treatment. Optimum topical treatments for OCD allow maximal contact time between the medicament with the affected oral mucosa. The use of adhesive pastes, such as agents containing mucin, is established to improve the effectiveness of such treatments. Mouthwashes are preferable, as they can readily treat oral mucosal disease that is extensive or over disparate sites. However, patients require clear instructions regarding their use, including the need to expectorate well afterwards to limit systemic uptake. A variety of formulations of various corticosteroids have been proposed, including dexamethasone suspension (0.1 mg/mL), clobetasol, 53 and non-corticosteroid-based agents, such as tacrolimus. These have proven benefit in a variety of immune-mediated diseases affecting the oral mucosa, with tacrolimus shown to be particularly effective in managing the oral lesions seen in OCD. 54 The value of these topical agents is often transient, and their use needs to be ongoing to maintain a clinical benefit. Concurrent use of topical antifungal agents (amphotericin, miconazole, or chlorhexidine) is recommended given the likelihood of such agents inducing oral candidiasis. Intra-lesional corticosteroids, such as triamcinolone, 55, 56 are also of benefit; however, injections are painful and must be repeated to achieve a sustained benefit. Topical or infiltrating local anesthetic agents can be used concurrently. Elimination diets are also often advocated, but these seemingly have greater benefit in patients with OFG than in patients with OCD. 57 Maintenance of good oral hygiene via regular dental review is important, especially for patients with gingival involvement. If clinically indicated, dental extractions are not contraindicated in patients with active or severe OCD and can significantly improve patient comfort.
Esophageal disease
Over 100 case reports of esophageal CD have been published since the first report in 1950 58 with almost all cases having concomitant intestinal disease. 59, 60 The prevalence of esophageal CD is 0.3-10% in adults. 15, 60 The mean age of diagnosis is 34 years, which is older than that of intestinal or oral CD and suggests delayed diagnosis typically following development of complications such as strictures. 60, 61 Wang et al. 11 proposed that esophageal CD progresses through three phases. The initial phase involves inflammation, edema, erosions, and linear ulcers. This then progresses to stenotic lesions with mucosal bridges, followed by progressive dysphagia, odynophagia, vomiting, and weight loss in the final phase. Most cases of esophageal CD are asymptomatic or mild with nonspecific upper GIT symptoms similar to gastroesophageal reflux disease. 25 The distal third of the esophagus is most commonly affected. 39 Eighty percent of patients have distal involvement alone, while 15% have distal and middle third involvement, and 5% have the entire esophagus involved. 59 Up to 50% of radiological investigations for esophageal CD are normal, and imaging investigations have been largely replaced by endoscopy. 39, 56, 57 On barium swallows, typical radiological findings include ulcers, "rose thorn" fissures, a cobblestone appearance of the mucosa, strictures, sinus tracts, polyps, and fistulae (Fig. 3) . Findings on other modalities are less specific, such as swelling and thickening of the esophageal wall seen on CT. Endoscopic findings are similarly variable and nonspecific. Early disease may be characterized by aphthous ulcers, granular and hyperemic mucosa, esophagitis, and superficial erosions (Fig. 4) , while more advanced disease may display cobblestone appearances, strictures, and fistulae into surrounding structures. 39, 59, [61] [62] [63] Histologically, granulomas may be found in 7-39% of patients; however, multiple, large, and deep biopsies are required to achieve maximal diagnostic yield. 9, 32 Treatment. There is a paucity of data examining the management options for esophageal involvement. Half of patients will Upper GI Crohn's Diseaseimprove on first-line agents, including 5-aminosalicylic acid, corticosteroids, histamine-2-receptor antagonists, and proton pump inhibitors (PPIs). 59, 62 Esophageal CD responds faster and more completely to corticosteroids than intestinal disease, with the majority of patients achieving complete resolution within 2 to 4 weeks of therapy. 64 Although acid suppressive therapy improves symptoms, it does not alter the underlying inflammatory process thus should be used in combination with anti-inflammatory therapy. 64, 65 Patients who do not respond to first-line therapy may benefit from a second-line immunomodulator such as 6-mercatopurine, azathioprine, cyclosporine, and thalidomide. 60, 62, 64 Infliximab is indicated for those refractory to first-line and second-line therapy and more severe disease manifesting as deep ulcers and cobblestone appearance. 63, 66 Endoscopic and surgical intervention is rarely required, but may be indicated for severe disease or on development of complications. 67 Esophageal dilatation and stenting are effective for dysphagia secondary to fibrotic strictures in 80% of cases, although these procedures carry risks of perforation, stricture recurrence, pain, and stent migration. 22, 68, 69 Perforation occurs in 0.1-0.4% of esophageal dilatation procedures, with irregular, long, or high-grade strictures carrying the greatest risk.
68,70 Surgical resection may be required for fistulae and extensive strictures that have failed medical management and/or dilatation. 25, 39, 71 Although there is no data on local recurrence of CD after esophagectomy, it remains a theoretical risk. 71 
Gastroduodenal disease
Gastroduodenal disease can be seen macroscopically in 30% and microscopically in up to 40% of CD patients. 69, [72] [73] [74] [75] The frequency of gastroduodenal CD appears to vary geographically with a recent prospective study, showing a prevalence of 16.5% in Eastern Europeans versus only 2% in Asian patients. 75 The gastric antrum and duodenal bulb are most frequently involved, while proximal gastric and distal duodenal involvement are uncommon. 24, 28, 32, 39, 72, 76 Upper GIT symptoms are experienced by fewer than 6% of CD patients, especially those with duodenal more so than gastric disease. 69 The most common symptom is postprandial dyspepsia 20, 31, 74 while nausea, anorexia, diarrhea, and weight loss can also occur. Severe disease with gastric outlet obstruction may cause early satiety, postprandial vomiting, weight loss, or in rare cases, hematemesis. 18, 22, 31, 37 Infrequently, biliary colic can occur secondary to involvement of papilla of Vater, 77 pancreatitis due to duodenal involvement, 78 or hemorrhage from vascular disruption. 39 Double-contrast barium meal or small bowel follow-through is neither sensitive nor specific for diagnosing gastroduodenal CD. 22 Classic radiographic findings like the Ram's horn (funnelshaped deformity of diseased antrum and duodenal bulb) are rarely seen. 3 Gastroduodenal CD may manifest radiologically as cobblestone appearance, thickened mucosal folds, aphthous or intramural ulcers, dilatation, strictures, and fistulae. 22, 39 Cases of widespread gastric involvement mimicking linitis plastica have been described, 79 and historically, up to one-third of patients required surgery for gastric involvement in order to exclude malignancy. 3 Magnetic resonance enterography is increasingly becoming the modality of choice when evaluating patients with established small bowel CD, replacing small bowel series and CT enterography. 80 While it is primarily used to evaluate the small bowel, especially the ileum, the stomach and duodenum may be partially included in the field of view, and disease involvement can sometimes be identified on the same study. The use of different pulse sequences, dynamic contrast-enhanced, and diffusionweighted imaging allows determination of disease activity, disease distribution, and any extra-luminal complications 81 ( Fig. 5) . Gastroscopy with biopsies is considered the gold standard in the diagnosis of gastroduodenal CD. Endoscopic findings may include aphthous ulceration, erosions, patchy erythematous mucosa, thickened folds, fistulae, and bamboo joint-like appearances (Fig. 6) . 5, 22, [82] [83] [84] Erosions are often irregular and longitudinal, while ulcers can be aphthoid, linear, stellate, or serpiginous. 20, 82 Bamboo joint-like lesions are specific for CD, appearing as erosive grooves intersecting longitudinal edematous gastric folds. 5 The duodenum may also exhibit a cobblestone appearance, polypoid lesions, and duodenal notching of Kerckring's folds, which is considered to be a pathognomonic sign. 24, 28, 32, 85 Strictures are found in up to 76% of cases and may prevent passage of the endoscope. 3, 20, 31 Focally enhanced gastritis, granulomas, and multinucleated giant cells are the main histological findings in gastroduodenal CD (Fig. 7) , with a prevalence of one or both in 76%. 74 Named by
Oberhuber et al., focally enhanced gastritis consists of focal collections of histiocytes and lymphocytes surrounded by gastric foveolae. 74, 86 Granulomas can be found either within focal lesions or in macroscopically normal mucosa. 5 Their overall prevalence ranges from 11% to 40%; however, this varies depending on location in the GIT as well as the number, depth, and quality of Upper GI Crohn's Diseasebiopsies. 15, 82, 84 The highest prevalence of granulomas is found in the gastric antrum (25%), followed by the duodenal bulb (11%) and the middle or proximal stomach (6%). 74, 82 Patient ethnicity also plays a role. Farkas et al. identified granulomas and focally enhanced gastritis in 7.6% and 23.8% of Hungarians compared with only 1% and 2% of Chinese patients, respectively. 75 Although focally enhanced gastritis is common, it is nonspecific. Similar histological features are seen in 12-24% of ulcerative colitis patients and in those without inflammatory bowel disease. 15, 86 In order to interpret these features, Helicobacter pylori infection must first be excluded using tests recommended by international guidelines, 87 as it can appear histologically identical to CD.
74
Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause ulceration that can also be mistaken for upper GIT CD. NSAID enteropathy is diagnosed through the history of NSAID use and presence of characteristic diaphragmatic strictures that typically differ to irregular small bowel strictures seen in CD. 88 Treatment. Anti-secretory agents, including PPI, are commonly used in upper GIT CD. Symptomatic relief for nonobstructive disease is offered, but there are little data to support their use. 25, 33, 37, 57, 69, 89 These agents are frequently commenced in those with upper GIT symptoms or upon diagnosis with upper GIT CD. 25 Similar to esophageal CD, PPI only suppresses the acid production but not the underlying inflammatory process, therefore leaving patients susceptible to disease progression. 33, 69 Nonsteroidal anti-inflammatory medications should be ceased, and eradication therapy should be administered if H. pylori is identified on investigations. In the presence of dual diagnoses, the recommendation is to treat the curable condition independently and ensure improvement through repeat endoscopic and/or other confirmatory tests.
General management principles
There are limited data on the specific management of upper GIT CD, due to its rarity and the frequent coexistence with distal disease, which necessitates standard therapy. Upper GIT CD is therefore treated using similar principles and modalities as distal disease. 22, 25, 38, 89, 90 Corticosteroids have remained the mainstay of medical therapy for upper GIT CD 24, 39 ; however, similar to distal disease, steroid refractory cases occur. 24, 33, 37 The Asia-Pacific consensus statement on CD recommends the use of azathioprine, 6-mercaptopurine, or methotrexate as steroid-sparing therapy in upper GIT CD, although there are limited data to support this. 37, 69, 89 Miehsler et al. 33 suggested that azathioprine was effective at maintaining remission, but not inducing remission. Similarly, there are a lack of clinical trials with sulfazalazine and mesalazine. Their release properties usually aim for the release of the active 5-aminosalicylic acid in the distal small intestine or colon, reducing their effects on the upper GIT but may offer some potential therapeutic benefit. 37 Infliximab is the most widely used biological agent for upper GIT CD and demonstrates improved disease activity scores and symptoms. 16, 52, [91] [92] [93] Annunziata et al. 18 performed a prospective study on 119 patients with CD, 19 of whom had upper GIT involvement. Of these 19 patients, 11 were treated with anti-TNF-α therapy (10 with infliximab and 1 with adalimumab), with or without other anti-inflammatory agents, while 8 were treated only with non-biological antiinflammatory therapy. After 12 weeks, the biological group had 8 of 11 patients experience significant macroscopic improvement and 7 with significant histological improvement. After the same time period, only 1 of 8 patients who did not receive a biological agent had evidence of macroscopic healing, and no patients had histological improvement.
Surgery
In the late 20th century, up to 40-50% of patients with complicated upper GIT CD required surgery after failing medical options. 39 This rate has since decreased to 10-20% of patients with upper GIT disease. 69 Strictureplasties and procedures that bypass the diseased segment (usually duodenum) such as gastrojejunostomy, duodenojejunostomy, and gastroduodenostomy operations are the most common surgical procedures performed for upper GIT disease. Endoscopic balloon dilatations are occasionally performed for single, short segment strictures; however, they are ineffective for long or multiple strictures. 94, 95 Resection is no longer preferred for gastroduodenal CD because of its higher morbidity and mortality rates compared with bypass procedures. 21, 90, 96 Conflicting results are apparent from a handful of studies comparing strictureplasty with bypass procedures for duodenal CD. Equal rates of symptomatic improvement have been reported with each procedure, 26 while bypass procedures have a greater risk of anastomotic leak and gastric outlet obstruction. 31 Strictureplasty offers theoretical advantages, including a lower risk of dumping syndrome, peptic ulcers, and bile reflux gastritis, 97, 98 although it has been associated with higher rates of wound and intraabdominal infections, primary failure, stricture recurrence, and reoperation. 31 Tonelli et al. 97 found that strictureplasty was effective for treating duodenal CD, particularly if the disease was confined to less than two strictures in the second and third parts of the duodenum. By contrast, Yamamoto et al. 98 identified a therapeutic benefit of strictureplasty for jejunoileal disease but not for duodenal involvement. In summary, bypass is generally the preferred technique when surgical intervention is required 25, 37, 69, 90, 96 ; however, strictureplasty may be indicated for specific circumstances, such as short segment strictures with limited edema, or shortbowel syndrome. 25, 99 The Asia-Pacific consensus guidelines for CD favor strictureplasty to resection so as to preserve small intestinal length. 89 For patients undergoing bypass or resection, laparoscopic procedures are preferred to open procedures. 100 Shapiro et al. 21 compared 11 patients undergoing open bypass with 13 patients undergoing laparoscopic bypass for duodenal CD. Notably more complications occurred in the open group (5 of 11 vs 1 of 13 in laparoscopy group), including persistent obstruction, anastomotic leak, and bleeding. The laparoscopy group also had faster postoperative recovery and shorter length of stay (mean 7 vs 12 days). Both methods had a similar rate of recurrence and requirement for further surgery. 21 
Prognosis
Upper GIT involvement predicts a more severe CD phenotype requiring more aggressive medical and surgical intervention. 19, 27, 30, 92 It is associated with more extensive intestinal and extra-intestinal manifestations. 19, 27, 29 In the pediatric population, upper GIT CD patients have a significantly higher Pediatric CD Activity Index at time of diagnosis compared with distal disease (41 vs 25, respectively). 27 Stricturing disease is more common with proximal disease (47%) versus distal disease (19%), leading to an increased risk of bowel obstruction and perforation. 19, 30, 92 With regard to penetrating disease that portends worse prognosis in CD, Chow et al. 30 found patients with proximal CD had a higher incidence of penetrating complications (30%) compared with those with distal disease (4%) in a Chinese cohort. Patients with upper GIT disease also have a higher incidence of inflammatory bowel disease associated arthritis compared with patients without upper GIT disease (37% vs 23%, respectively). 19, 27, 29 Proximal disease requires more aggressive medical management compared with distal disease, including a higher dose of corticosteroids (63 vs 45 m/kg), immunomodulators (50% vs 29%), and double the number of infliximab infusions. 27 This group also has more surgical procedures, with 67% requiring surgery compared with 36% of patients with distal disease 19, 30 and a mean of 1.1 versus 0.8 procedures per patient, respectively. 19 Disease recurrence is common. Ross et al. 101 followed a cohort of patients for a mean of 13.9 years after surgical intervention for duodenal disease and found that 70% required repeat operations at the same site and the same number required future operations elsewhere in the GIT. Reoperation at the same site was performed after a mean of 7.7 years.
Conclusion
Upper GIT CD disease is an under-recognized condition. Its presentation is frequently mild and nonspecific; however, severe manifestations such as gastric outlet obstruction can occur. A high index of suspicion is therefore required. Multidisciplinary clinics comprising gastroenterologists, radiologists, and upper GIT surgeons, with other specialists (such as dentists and oral medicine specialists), could improve diagnosis and management. Routine gastroscopy is recommended in all CD patients presenting in the pediatric age group regardless of symptomatology. There is a paucity of literature on effective medical management options for upper GIT CD, and current practices therefore closely reflect those for distal disease. Proximal disease has a worse prognosis and requires more aggressive medical therapy and a higher rate of surgical intervention. More prospective studies are needed in the future to provide further insight into disease management and long-term prognosis.
